A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
Open Access
- 22 January 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (4) , 680-687
Abstract
This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 1) in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Patients with advanced HCC (stratified by Barcelona Clinic Liver Cancer stage and Eastern Cooperative Oncology Group performance status) were randomized 1:1 to receive sorafenib (400 mg, twice daily per 21-day cycle) and either placebo (placebo–sorafenib arm) or mapatumumab (30 mg/kg on day 1 per 21-day cycle; mapatumumab–sorafenib arm). The primary end point was time to (radiologic) progression (TTP), assessed by blinded independent central review. Key secondary end points included progression-free survival, overall survival, and objective response. In total, 101 patients were randomized (placebo–sorafenib arm: N = 51; mapatumumab–sorafenib arm: N = 50). There was no significant difference in median TTP between both arms [5.6 versus 4.1 months, respectively; adjusted hazard ratio (one-sided 90% confidence interval) 1.192 (0–1.737)]. No mapatumumab-related benefit was identified when TTP was evaluated in the stratified subgroups. The addition of mapatumumab to sorafenib did not demonstrate improvement in the secondary efficacy end points. The reported frequency of adverse events (AEs) and serious AEs was comparable in both treatment arms. The addition of mapatumumab to sorafenib did not improve TTP or other efficacy end points, nor did it substantially change the toxicity profile of sorafenib in patients with advanced HCC. Based on these results, further development of the combination of mapatumumab and sorafenib in HCC is not planned.Keywords
Funding Information
- GlaxoSmithKline
- GlaxoSmithKline
This publication has 41 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Current Strategy for Staging and Treatment: The BCLC Update and Future ProspectsSeminars in Liver Disease, 2010
- Trail Receptors: Targets for Cancer Therapy2008
- Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesisWorld Journal of Gastroenterology, 2008
- Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1Journal of Clinical Oncology, 2007
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver MetastasesMolecular Therapy, 2004
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 1999
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995